BEAM THERAPEUTICS REPORTS UPDATED DATA FROM BEACON PHASE 1/2 TRIAL OF RISTOGLOGENE AUTOGETEMCEL (RISTO-CEL) HIGHLIGHTING DURABLE, DIFFERENTIATED PROFILE IN SICKLE CELL DISEASE (SCD) AT AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING

Reuters · 1d ago

Please log in to view news